Evidence map›Paper›PMID 24665414›Full record

ArticleCurrent treatment options in psychiatry2014

Cognition in Late Life Depression: Treatment Considerations.

Aaron M Koenig, Meryl A Butters

Abstract read
In one paragraph

Article in Current treatment options in psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Exercise for Cognitive Symptoms in Depression: A Systematic Review of Interventional Studies.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2018
    Pooled it
  2. Review
  3. Article
  4. Cognitive Impairment Evaluation and Management.The Medical clinics of North America · 2020
    Review
  5. [Depression in old age, part 2 : Comorbidity and treatment].Zeitschrift fur Gerontologie und Geriatrie · 2016
    Review
  6. Treatment resistant depression or dementia: a case report.Shanghai archives of psychiatry · 2016
    Article
  7. Review
  8. Review
  9. Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option?Clinical practice and epidemiology in mental health : CP & EMH · 2015
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Aaron M KoenigDepartment of Psychiatry, University of Pittsburgh School of Medicine (Pittsburgh, PA, USA).
Meryl A ButtersDepartment of Psychiatry, University of Pittsburgh School of Medicine (Pittsburgh, PA, USA).

Funding

Amyloid, White Matter Hyperintensities & Outcomes of Late-Life DepressionR01MH080240 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BUTTERS, MERYL A · 2009 to 2014
$2.6M
Pathways Linking Late-Life Depression to MCI &DementiaR01MH072947 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BUTTERS, MERYL A · 2005 to 2009
$2.0M
NIMH NIH HHS R01 MH072947NIMH NIH HHS R01 MH080240
6 · The paper itself

Abstract

Late life depression (LLD) frequently presents with cognitive impairment, and growing evidence suggests that these disease processes are "linked" in multiple ways. For some individuals, LLD may be a recurrence of a long-standing depressive illness, while for others it may be the leading symptom of a developing neuropathological disorder. Overall, studies investigating the relationship between treatment of LLD and improvement in cognitive functioning have yielded mixed results. Research suggests that a subset of individuals with LLD and cognitive dysfunction will experience an improvement in cognitive function after antidepressant treatment, though a significant proportion will continue to exhibit cognitive impairment following resolution of their depressive symptoms. From a treatment standpoint, it is critical to ensure that an individual's depressive symptoms have been treated to remission, measured by a standardized rating scale such as the Geriatric Depression Scale (GDS). SSRI or SNRI monotherapy is often effective, and may be enhanced by employing an evidence-based psychotherapy such as Problem Solving Therapy (PST) or Interpersonal Therapy (IPT), modified to accommodate cognitive impairments that may be present. With respect to specific treatment of cognitive dysfunction, cognitive augmentation or training strategies can be helpful for some patients, and may be explored in combination with treatment of the primary depressive episode. While the introduction of a cholinesterase inhibitor (e.g. donepezil) may be considered, the potential benefit (modest improvement in cognition and functioning) must be weighed against an increased risk for worsening or recurrent depression. Finally, lifestyle factors-such as aerobic exercise, follow-up with a primary care physician for management of co-morbid medical illnesses, and regular participation in stimulating activities (such as through a senior center)-are important and should be included as part of the overall treatment plan.

Indexed as

antidepressantcognitive trainingdementiaelectroconvulsive therapyemerging treatmentslate-life depressionmild cognitive impairmentpharmacotherapypsychotherapytreatment

Identifiers

PMID24665414
PMCPMC3961714

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.